CXS Chemgenex Fpo

ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced today that it will deliver a presentation at the 27th Annual Canaccord Adams Global Growth Conference in Boston, Massachusetts. Greg Collier, Ph.D., Chief Executive Officer and Managing Director of ChemGenex, is scheduled to present to leading institutional investment representatives at 10am on Thursday, August 9, 2007, at the InterContinental Boston. �We look forward to showcasing ChemGenex to international investors at this year�s Growth Conference,� said Dr. Collier. �This is an ideal venue at which to provide an update of our registration-directed clinical program in chronic myeloid leukemia (CML) patients with the T315I BCR-ABL point mutation and other corporate activities.� An audio webcast of the presentation will be available from the company's website, www.chemgenex.com one hour after the completion of the presentation, and will be available for 90 days after the conference. The Canaccord Adams Global Growth Conference is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Many of the presenting public companies are covered by Canaccord Adams� global team of equity analysts. About ChemGenex Pharmaceuticals Limited (www.chemgenex.com) ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing therapeutics in the areas of oncology, diabetes and obesity. ChemGenex harnesses the power of genomics for target discovery and validation, and in clinical trials to develop more individualized therapeutic outcomes. ChemGenex�s lead compound, Ceflatonin�, is currently in phase 2/3 clinical trials for chronic myeloid leukemia (CML) and Quinamed� is in phase 2 clinical development for prostate, breast and ovarian cancers. The company has a significant portfolio of anti-cancer, diabetes and obesity programs, several of which have been partnered with international pharmaceutical companies. ChemGenex currently trades on the Australian Stock Exchange under the symbol "CXS" and on NASDAQ under the symbol "CXSP". Safe Harbor Statement Certain statements made herein that use the words �estimate�, �project�, �intend�, �expect�, �believe� and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company�s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company�s technology, the market for the company�s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management�s current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.